Chandan Healthcare Ltd · CHANDAN
—
—
—
—
₹55 Cr
₹63 Cr
₹68 Cr
₹68 Cr
₹65 Cr
₹76 Cr
₹81 Cr
20-quarter listed-company comparison
Diagnostic Services Stocks in India
Diagnostic Services: 1 companies, compared one question at a time.
01 · the index people search for
Nifty Diagnostic Services Index — Constituents & Performance
All 1 listed Indian Diagnostic Services companies are named here, largest first — the same constituent set people search for as the Nifty Diagnostic Services index. Every figure on this page is equal-weighted across those companies, so one large constituent cannot set the reading. Each number carries its own as-of date.
- Chandan Healthcare Ltd₹606 Cr
02 · sector relative strength, before individual stocks
Is Diagnostic Services outperforming NIFTY 500?
Diagnostic Services has underperformed NIFTY 500 by 8.9% over the last 52 weeks. Over 13 weeks the gap is a shortfall of 3.6%. 0 of 1 covered company currently beat NIFTY on Mansfield relative strength, so leadership inside the sector is selective. Chandan Healthcare Ltd is the strongest against the sector itself at 0%.
-3.6%Sector vs NIFTY 500 · 13 weeks
-8.9%Sector vs NIFTY 500 · 52 weeks
0/1Stocks leading NIFTY 500
0/1Stocks leading sector
Sector metric: — as of latest available · unclassified · direction unavailable.
The central tension: current leadership is concentrated, so durability matters more than rank.
Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.
Bottom line
Diagnostic Services has underperformed NIFTY 500 by 8.9% over 52 weeks and 3.6% over 13 weeks. 0 of 1 covered companies beat NIFTY on Mansfield relative strength, while 0 of 1 beat the sector itself. Chandan Healthcare Ltd leads with revenue of ₹289 crore, based on 1 of 1 comparable companies through Jun 2026.
Companies
1
complete canonical membership
Combined market value
₹606 Cr
Chandan Healthcare Ltd
Revenue growing
—
positive TTM year-on-year growth
Beating NIFTY 500
0/1
positive Mansfield relative strength
Comparing 1 of 1
03 · research priority, made explicit
Best Diagnostic Services Stocks in India (Aug 2026), Ranked by Data
4-Factor Sector Score
An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.
Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%
Chandan Healthcare Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 53.5% evidence confidence.
How this score is built, and what the marks mean
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Top 10 Diagnostic Services Stocks in India
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Chandan Healthcare LtdCHANDAN | 56.9/100Thin evidence · provisional54% evidence | ASLEEP | 17.9/35 Revenue — · PAT — · OPM change 3.8 pp 45% evidence | 21.5/25 ROCE 23.1% · OPM 24.2% 95% evidence | 10.0/20 P/E 23.1× · PEG — 0% evidence | 7.5/20 RS sector 0% · RS bench -7.8% · 1Y 3.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 17.9 + 21.5 + 10 + 7.5 = 56.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
04 · what price has already done
Market action
Chandan Healthcare Ltd has the strongest one-year price move in Diagnostic Services at +3.3%. It also leads on Mansfield relative strength against NIFTY at -7.8%. 0 of 1 covered company are above zero on that measure. Every line covers 313 weekly closes through 2026-08-14.
Price and relative strength
Every company, the sector's own index and NIFTY 500 all start level on the left edge of the window, so only the distance between the lines counts — the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.
How far ahead of or behind NIFTY 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS NIFTY 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.
The same measure taken against Diagnostic Services itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.
05 · compare level, then change
Revenue Scale & Growth Durability
Chandan Healthcare Ltd is the only Diagnostic Services company on this page, with Revenue of ₹289 crore. That is the only usable Revenue reading on this page, current through Jun 2026. Its Revenue series carries 7 reported observations across the 11-quarter window.
What the numbers say: Chandan Healthcare Ltd leads revenue at ₹289 crore; the second comparison lacks enough current evidence.
LeaderChandan Healthcare Ltd · ₹289 crore
GapNot enough peers
Persistence3/3 recent comparable periods
Coverage1/1 companies · 7 observations
Investor read: Chandan Healthcare Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current revenue growth signal.
Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenuelargest
Revenue growthfastest growers
—Not enough comparable data—
Revenue · company comparison
1/1 level · 0/1 change
On every company-comparison chart on this page: solid lines show level, dotted lines show change when “Both” is selected, and a missing report breaks the line rather than being invented.
All-company data · latest reported quarter
In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Revenue | Revenue growth | Reported |
|---|---|---|---|
| Chandan Healthcare Ltd CHANDAN | ₹81 Cr | 19% | Jun 2026 |
Full 11-quarter history · every available company
Revenue · reported quarter history
Revenue growth · reported quarter history
Chandan Healthcare Ltd · CHANDAN
—
—
—
—
—
—
—
—
19%
21%
19%
06 · compare level, then change
Operating Economics & Margin Trend
Chandan Healthcare Ltd is the only Diagnostic Services company on this page, with OPM of 24.2%. The same company also holds the highest Margin change, at +3.8 percentage points. That is the only usable OPM reading on this page, current through Jun 2026. Its OPM series carries 9 reported observations across the 11-quarter window.
What the numbers say: Chandan Healthcare Ltd leads both opm at 24.2% and margin change at +3.8 percentage points.
LeaderChandan Healthcare Ltd · 24.2%
GapNot enough peers
Persistence4/5 recent comparable periods
Coverage1/1 companies · 9 observations
Investor read: Chandan Healthcare Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current margin change signal.
Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
OPMhighest
Margin changefastest expanders
Operating margin · company comparison
1/1 level · 1/1 change
All-company data · latest reported quarter
| Company | OPM | Margin change | Reported |
|---|---|---|---|
| Chandan Healthcare Ltd CHANDAN | 24% | +3.8 pp | Jun 2026 |
Full 11-quarter history · every available company
OPM · reported quarter history
Chandan Healthcare Ltd · CHANDAN
—
—
15%
18%
16%
16%
20%
21%
18%
15%
24%
Margin change · reported quarter history
Chandan Healthcare Ltd · CHANDAN
—
—
—
—
—
+1.4 pp
—
+2.9 pp
+1.9 pp
−1.2 pp
+3.8 pp
07 · compare level, then change
Profit Scale & Acceleration
Chandan Healthcare Ltd is the only Diagnostic Services company on this page, with Net profit of ₹25 crore. That is the only usable Net profit reading on this page, current through Jun 2026. Its Net profit series carries 7 reported observations across the 11-quarter window.
What the numbers say: Chandan Healthcare Ltd leads net profit at ₹25 crore; the second comparison lacks enough current evidence.
LeaderChandan Healthcare Ltd · ₹25 crore
GapNot enough peers
Persistence2/3 recent comparable periods
Coverage1/1 companies · 7 observations
Investor read: Chandan Healthcare Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.
Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profitlargest
Profit growthfastest growers
—Not enough comparable data—
Net profit · company comparison
1/1 level · 0/1 change
All-company data · latest reported quarter
| Company | Net profit | Profit growth | Reported |
|---|---|---|---|
| Chandan Healthcare Ltd CHANDAN | ₹8 Cr | 28% | Jun 2026 |
Full 11-quarter history · every available company
Net profit · reported quarter history
Chandan Healthcare Ltd · CHANDAN
—
—
—
—
₹4 Cr
₹6 Cr
₹6 Cr
₹8 Cr
₹5 Cr
₹5 Cr
₹8 Cr
Profit growth · reported quarter history
Chandan Healthcare Ltd · CHANDAN
—
—
—
—
—
—
—
—
8.1%
-18%
28%
08 · compare level, then change
Return On Capital Employed
Chandan Healthcare Ltd is the only Diagnostic Services company on this page, with ROCE of 23.1%. The same company also holds the highest ROCE change, at -6 percentage points. That is the only usable ROCE reading on this page, current through Jun 2026.
What the numbers say: Chandan Healthcare Ltd leads ROCE at 23.1%. Chandan Healthcare Ltd has the strongest latest improvement at -6 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.
LeaderChandan Healthcare Ltd · 23.1%
GapNot enough peers
PersistenceNot enough history
Coverage1/1 companies · 0 observations
Investor read: Chandan Healthcare Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current roce change signal.
ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
ROCEhighest
ROCE changefastest improvers
Return on capital · company comparison
1/1 level · 1/1 change
All-company data · latest reported quarter
| Company | ROCE | ROCE change | Reported |
|---|---|---|---|
| Chandan Healthcare Ltd CHANDAN | 23% | −6.0 pp | Jun 2026 |
Full 11-quarter history · every available company
No consistent historical series is available for roce.
No consistent historical series is available for roce change.
09 · compare level, then change
Valuation Against Growth & Quality
No company in this Diagnostic Services comparison reports a valuation figure this section can compare, so the PEG rank is empty. On P/E, Chandan Healthcare Ltd is lowest at 23.1×, across 1 of 1 company with a usable reading. PEG asks what price is being paid for growth; P/E keeps that answer anchored to the actual earnings multiple.
What the numbers say: There is not enough comparable evidence to name a reliable peg leader.
LeaderNo comparable leader
GapNot enough peers
PersistenceNot enough history
Coverage0/1 companies · 0 observations
Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.
This conclusion weakens if: The next two comparable reports reverse the current p/e signal.
PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.
PEGlowest PEG
—Not enough comparable data—
P/Elowest P/E
Valuation · company comparison
0/1 level · 1/1 change
All-company data · latest reported quarter
| Company | PEG | P/E | Reported |
|---|---|---|---|
| Chandan Healthcare Ltd CHANDAN | — | 30.9 | Jun 2026 |
Full 11-quarter history · every available company
No consistent historical series is available for peg.
P/E · reported quarter history
Chandan Healthcare Ltd · CHANDAN
—
—
—
—
—
22.2
22.9
25.6
29.2
22.0
30.9
10 · before the conclusion, check the blind spots
What can make this comparison misleading?
This Diagnostic Services comparison names 5 specific ways its own evidence can mislead, all listed below. The one company here reports on comparable dates, so no rank carries a stale marker. 1 of the 5 ranked sections has fewer than three usable current readings. A high growth rate can still be a low-base artefact.
Keep these limits visible
- A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
- A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
- The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
- Thin comparisons: Valuation have fewer than three usable current readings.
11 · evidence and freshness
How was this comparison built?
This comparison is built from the reported filings of 1 Diagnostic Services company, normalized to a common ₹ scale and a shared quarter axis of up to 11 quarters each. Fundamentals run through Jun 2026 and market data through 2026-08-14. A second data feed fills gaps only after identity and scale reconciliation, and missing observations are never interpolated.
FundamentalsThrough Jun 2026 · up to 11 quarters per company
Market dataThrough 2026-08-14 · weekly price and relative-strength history
Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.
Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.
Source standing0 cross-checked · 1 unverified · 0 withheld, of 1 graded companies.
How a second data feed is admitted, and what happens when it disagrees
A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree the figures fill silently. Where there is too little shared history to compare, the figures are still drawn — they are the only evidence there is — and marked ⚠ unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from.
12 · questions investors ask, short speakable answers
Diagnostic Services company comparison FAQs
These 20 answers restate the Diagnostic Services comparison above in question form. Every one is computed from the same 1 company and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-08-14. Nothing here is estimated, and none of it is a recommendation.
Is the Diagnostic Services sector outperforming NIFTY 500?
Diagnostic Services has underperformed NIFTY 500 by 8.9% over 52 weeks and 3.6% over 13 weeks. 0 of 1 covered companies beat NIFTY on Mansfield relative strength, while 0 of 1 beat the sector itself.
Which Diagnostic Services company is largest by revenue?
Chandan Healthcare Ltd leads with revenue of ₹289 crore, based on 1 of 1 comparable companies through Jun 2026.
Which Diagnostic Services company has the strongest 4-Factor Sector Score?
Chandan Healthcare Ltd ranks first at 56.9/100 with 53.5% evidence confidence. The score prioritizes research; it is not a buy recommendation.
How much history does this Diagnostic Services comparison include?
The page compares up to 11 reported quarters per company for fundamentals, returns and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.
How is the 4-Factor Sector Score calculated?
The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.
Is there a Nifty Diagnostic Services index?
NSE India maintains Nifty indices for several broad sector categories — Nifty Bank, Nifty IT, Nifty Pharma and others — but not for every sub-sector grouping on this site. Whether or not an official Nifty index covers Diagnostic Services, this page builds its own equal-weight basket of 1 listed Diagnostic Services companies — one company, one vote, regardless of market value — so no single large company dominates the reading. Figures are as of Jun 2026.
Which are the best Diagnostic Services stocks in India?
Ranked by this page's four-factor score, Chandan Healthcare Ltd places first among 1 listed Diagnostic Services companies. That is a ranking of published data — earnings, quality, valuation and market behaviour as of Jun 2026 — and not a recommendation; Sector Alpha is not registered with SEBI as an investment adviser.
How many Diagnostic Services stocks are listed in India?
This comparison covers 1 listed Diagnostic Services companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Jun 2026.
Which Diagnostic Services company is the biggest?
Chandan Healthcare Ltd is the largest, with trailing-twelve-month revenue of ₹289 crore. That covers 1 of 1 companies with comparable reporting through Jun 2026.
Which Diagnostic Services company has the best profit margins?
Chandan Healthcare Ltd has the highest operating margin at 24.2%, from 1 of 1 comparable companies. Chandan Healthcare Ltd shows the biggest recent improvement, at +3.8 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.
Which Diagnostic Services company makes the most profit?
Chandan Healthcare Ltd earns the most, at ₹25 crore of trailing-twelve-month net profit, from 1 of 1 comparable companies.
Which Diagnostic Services company earns the highest return on capital?
Chandan Healthcare Ltd leads on return on capital employed at 23.1%, across 1 of 1 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.
Is the Diagnostic Services sector beating the market?
Diagnostic Services has underperformed NIFTY 500 by 8.9% over the last 52 weeks and 3.6% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 0 of 1 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.
Which Diagnostic Services stock has the strongest price momentum?
Chandan Healthcare Ltd has the strongest relative strength against NIFTY 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.
Which Diagnostic Services company scores highest for research priority?
Chandan Healthcare Ltd scores 56.9 out of 100 with 53.5% evidence confidence, from 17.9 points on growth and earnings, 21.5 on capital efficiency, 10 on valuation and 7.5 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.
How many Diagnostic Services companies does this comparison cover, and over what period?
It compares 1 listed companies over up to 11 reported quarters of fundamentals, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.
What is the total market cap of the Diagnostic Services sector?
The 1 Diagnostic Services companies on this page carry ₹606 crore of combined market value. Chandan Healthcare Ltd is the largest at ₹606 crore, about 100% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-16.
How is the Diagnostic Services sector performing?
0 of the 1 covered Diagnostic Services companies are beating NIFTY 500 on Mansfield relative strength. The sector itself is 8.9% behind NIFTY 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-16.
Why are some values on this page blank?
A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.
Is this investment advice?
No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.